Benign prostate hyperplasia (BPH) is a common disease in elderly men. Although it is a nonmalignant disease, it has a significant detrimental impact on the quality of life in patients with latestage disease. Owing to the lack of specific markers, diagnosis of early-stage BPH has been proven unsuccessful. Recently, using two-dimensional electrophoresis, we identified a group of prostatic secretory proteins that are specifically produced by BPH cells (Xu et al., Electrophoresis 2003; 24: 1311). In this study, we investigated the potential diagnostic value of one of the secretory proteins, as1-Casein, in BPH by inmmunohistological staining of normal, BPH and prostate cancer tissues. We found that 90% (20 out of 22) of BPH tissues showed moderate to strong as1-Casein protein expression whereas none of the normal tissues (0 out of 10) and less than 10% of the prostate cancer tissues (3 out of 30) showed similar staining intensity. Our results suggest that as1-Casein may be a potential biomarker for early identification of BPH patients.
Introduction
Benign prostate hyperplasia (BPH) is a common disease in male population. It is reported that 14% of men aged between 40 and 50 years develop a degree of BPH and the incidence rate increases to 43% by the age of 60 years. 1 Benign prostate hyperplasia is a gradual enlargement of the prostate gland related to male aging and has a significant detrimental impact on a patient's quality of life. If left untreated, it may lead to recurrent bladder infection, bladder calculi and acute urinary retention, and eventually surgical intervention. 2 Although BPH is one of the most common diseases affecting aging men, surprisingly little is known about its etiology and pathophysiology. The initial BPH symptoms are mild, which may not draw much attention to the patients but at late stage, it will result in impairment of the function of the urinary bladder leading to induce detrusor instability, decreased compliance, even detrusor failure. 3 Although transurethral prostatectomy (TURP) is considered as a gold standard treatment for the surgical management of BPH, there is a high incidence of complications such as retrograde ejaculation (70%) and urinary incontinence (2%). 4 Recently, a number of studies reported that early administration of a 5-alpha reductase inhibitor (Proscar) to BPH patients is able to reduce the chance of prostate surgery by around 50%. 5 However, owing to the lack of reliable biomarkers for early detection, majority of BPH patients are presented at late stage, which may not be reverted even after TURP. 6 Therefore, early detection as well as prevention of the progression of this disease is essential for the successful treatment of BPH.
Several currently used markers such as prostatic acid phosphotase (PAP) and prostatic-specific antigen (PSA) have not been successful in early detection of BPH, although they have been helpful in diagnosis of prostate cancer. 1, 7, 8 Prostatic-specific antigen is currently the best and most useful marker for prostate cancer. 9, 10 However, it cannot accurately differentiate BPH from prostate neoplasm, because of a great deal of overlapping in PSA levels between BPH and prostate cancer, especially in the borderline cases (with PSA level between 4 and 10 ng/ml). 8, 9 Attempts have been made to improve the accuracy of diagnosis in the borderline zone, by measuring the ratio between free PSA and total PSA, or a combination of PSA and human kallikrein 2 (hK2). 11 However, a significant number of patients are still wrongly classified. Recent attempts have been made by several laboratories worldwide focusing on identification of specific markers for BPH. For example, Mikolajczyk et al. 12 have reported an elevation of a modified form of free PSA in prostatic tissues as well as seminal plasma from BPH patients, which is referred to as BPH-associated PSA (BPSA). However, although BPSA can be detected in patients with nodular enlargement of hyperplastic prostate, it is usually at a relatively late stage in the development of BPH. 12, 13 Recently, using two-dimensional gel electrophoresis, we identified a group of prostatic secretory proteins specifically present in human expressed prostatic secretion (EPS) from BPH patients.
14 Subsequent analysis showed that one of the proteins is as1-Casein, a protein that is usually produced by mammary epithelial cells. 14 The aim of this study was to investigate the possible usefulness of as1-Casein in the differential diagnosis between BPH and prostate cancer, and its possibility as a specific marker for BPH.
Materials and methods

Tissue samples
All prostate tissues were obtained from the archival tissue bank in the Department of Pathology, People's Hospital, Peking University, Beijing, China, either from suprapubic prostatectomy (BPH patients, n ¼ 22), radical prostatectomy (prostate cancer patients, n ¼ 30) or autopsy (normal prostate tissues, n ¼ 10). The average age of BPH is 67.5 years (range 59-90 years) and the average of prostate volume is 50.6 ml (range 30-120 ml). The pathological definition of BPH is a benign (noncancerous) condition in which an overgrowth of prostate tissue pushes against the urethra (which passes through the prostate) and the bladder, blocking the release of urine. The diagnosis of BPH was based on pathological examination including the International Prostate Symptom Score, residual volume, prostate volume, flow rate and PSA level. With hyperplasia, there is also an abnormal increase in the number of the prostate cells. The age of the autopsy specimens ranged from 36 to 54 years (46.7 years on average). The weights/volumes of the prostate were 40-80 ml (53.1 ml on average) with no lower urinary tract symptoms or BPH confirmed by pathological examination. All the control samples were pre-screened by pathologists to ensure that all of the specimens were BPH free. All specimens were examined by two pathologists in the Department of Pathology, People's Hospital of Peking University to verify previous diagnosis before used in the current study.
Production of antibody against recombinant as1-Casein
As commercial antiserum against as1-Casein was not available, polyclonal antibody against as1-Casein was produced using synthetic peptide by Zymed Laboratories Inc. (South San Francisco, CA, USA). Briefly, the cterminal sequence of NH 2 -CSD/ISN/PTA/HEN/YEK/ NNV/MLQ/W-COOH was synthesized and used as a recombinant immunogen. The quality of the peptide was analyzed by high-pressure liquid chromatography and mass spectroscopy. Two rabbits were immunized with the synthetic immunogen, which was conjugated to a carrier protein (KLH) via an added cysteine. Four weeks later, the serum samples of the rabbits were obtained, and enzyme-linked immunosorbent assay test as well as sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) was conducted to determine the titer and specificity before used for subsequent immunohistochemistry and Western blotting analysis.
Western blotting
Detailed experimental procedures have been described in one of our previous publications. 15 Briefly, protein concentration was quantified using the DC Protein Assay kit (Bio-Rad, USA). Fifty micrograms of protein was mixed with Â 6 sample buffer (0.1 M Tris-HCl (pH 6.8), 20% glycerol, 4% sodium dodecyl, 2% b-glycerolphosphate, bromophenol blue) and SDS-PAGE was carried out on 7.5-15% self-cast mini-gels using the Mini-PROTEAN II Electrophoresis Cell (Bio-Rad, USA) at a voltage of 40 V under a cooling condition for 2-5 h. The membrane was then probed with an appropriately diluted primary antibody for 14-16 h with gentle agitation at 41C. After rinsing, the membrane was incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (1:2000) (Amersham Pharmacia Biotech, USA) for 1 h at room temperature. The chemiluminescent signals were developed by ECL Plus Western blotting detection system (Amersham Pharmacia Biotech, USA) according to the manufacturer's manual.
Immunohistochemistry
Immunohistochemistry staining was performed using the Vectastain Elite ABC kit (Vector Laboratory, Burlingame, CA, USA) as described previously. 16 Briefly, sections were deparaffinized in xylene and rehydrated in graded alcohol and distilled water. The endogenenous peroxidase activity was blocked with 1% hydrogen peroxide in distilled water for 10 min, followed by washing in phosphate-buffered saline (PBS) and incubation with normal goat serum for 30 min to bind nonspecific antigens. The slides were then incubated overnight at 41C with appropriately diluted primary antibody against as1-Casein (1:200, Zymed). After several rinses in PBS, the slides were incubated with the biotinylated anti-rabbit IgG at the dilution of 1:200 for 30 min at room temperature followed by peroxidaseconjugated avidin-biotin complexes (ABC, Vectastain Elite) and 3,3 0 -diaminobenzidine (DAKO, Carpinteria, CA, USA). The sections were then counterstained with Mayer's haematoxylin and dehydrated through 70% alcohol, 100% alcohol to xylene and then mounted. The slides were analyzed by standard light microscopy.
Quantitation of immunostaining results
The as1-Casein immunoreactivity was quantitated using computerized image analysis (Leica QWin Image Processing and Analysis System, Leica Imaging System Ltd, Cambridge, UK). All sections were immunostained at the same time under the same conditions in order to reduce the variability. Five fields (under a Â 400 objective) from each prostate section were randomly selected for assessment according to a pre-defined grid pattern. Images were imported into the Qwin imaging program using a color video camera and a standard light microscope. The detection level threshold for positively stained areas (brown color for positive staining) was set. An average intensity and area of staining was determined by calculating the number of selected positive pixels (above threshold) in a given area and expressed as a percentage of the entire image. According to the quantitative data, the staining was scored as '
representing negative, weak, moderate and strong staining intensity, respectively.
Statistical analysis
Statistical analysis was performed using the SPSS statistical software (SPSS Inc, Chicago, IL, USA). The analysis of the expression level of as1-Casein between BPH, prostate cancer and normal prostate specimens was performed by an unpaired Student's t-test. Probability levels of less than 0.05 were taken to indicate statistical significance.
Results
Presence of as1-Casein in human expressed prostatic secretion samples from benign prostate hyperplasia patients
Previously, using two-dimensional electrophoresis, we identified several secretory proteins specifically present in the EPS samples from BPH patients. One of them was recently identified as as1-Casein (one of the proteins presented in Spot 3). 14 In this study, to confirm the twodimensional results and further study the significance of as1-Casein expression in BPH patients, we first performed Western blotting to study the as1-Casein protein expression in EPS derived from BPH patients and BPHfree controls. As shown in Figure 1 , specific as1-Casein bands with molecular weights of 45 and 10 kDa were detected in BPH-EPS whereas no corresponding bands were found in the BPH-free controls when same amount of protein was analyzed. It is possible that the 10 kDa band could be a degradation form of as1-Casein, which was also detected by our previous 2-D and MS analysis. 14 Expression of Actin was also examined to demonstrate equal loading among the samples. These results further confirmed our previous findings, suggesting that as1-Casein is uniquely secreted by BPH cells.
Upregulation of as1-Casein in benign prostate hyperplasia prostate tissues
It is possible that the increased secretory as1-Casein protein in the EPS samples could be the result of upregulation of as1-Casein protein expression in the BPH cells, which is then released into the prostatic secretion. To test this hypothesis, immonohistochemical staining was performed on pathological specimens obtained from 22 patients diagnosed with BPH, 30 patients with prostate cancer, respectively as well as 10 normal prostate tissues. As shown in Figure 2 , as1-Casein was undetectable in the epithelium of the normal tissues (panel a). In contrast, heavy as1-Casein staining was observed in the cytoplasm of hyperplastic prostatic epithelium (panels b and c, solid arrows) as well as in the prostatic secretion (panel c, dotted arrow). However, in prostate cancer cells, the staining intensity was weak or undetectable (panels d and e). Semiquantitative analysis showed that 20 out of 22 BPH tissues (90%) had moderate to strong positive staining intensity for as1-Casein (indicated as ' þ þ ' to ' þ þ þ ') ( Table 1) . In contrast, all 10 normal prostate tissues (100%) and majority of prostate cancer tissues (27 out of 30, 90%) showed negative or low reactivity ( Figure 3 and Table 1 ). In prostate cancer tissues, moderate staining intensity was only observed in three of the well-differentiated prostate cancer samples (Figure 2d ), whereas negative staining was observed in all of the poorly differentiated prostate cancer specimens (Figure 2e ). To further confirm the specificity of as1-Casein staining, we also performed the immunostaining using an antibody against b-casein, as shown in Figure 2f , no reactivity was observed in BPH tissues.
Discussion
In this study, we demonstrate a specific biomarker, as1-Casein, in BPH. The fact that elevated as1-Casein protein was detected in both BPH tissue samples and EPS but not in normal or malignant prostate tissues indicates a novel diagnostic marker for BPH patients. In contrast to PSA, which is secreted by both BPH and prostate cancer cells, as1-Casein seems to be uniquely produced by BPH epithelial cells indicating that it may play an important role in the development of BPH.
To date, there are no effective markers that can identify early BPH changes in the prostate before it causes clinical symptoms. The existing well-known markers, such as PAP and PSA, although useful in diagnosis of prostate cancer, are not very helpful in early detection of BPH (Omacini et al., 1992; Barichello et al., 1995; Partin and Marks, 2001). As a result, a significant number of patients are still wrongly diagnosed. Our results generated from this study suggest a novel specific marker for BPH. as1-Casein was uniquely detected in EPS obtained from BPH patients but not normal male or prostate cancer specimens (Figures 1 and 2) . Immunohistochemistry study revealed that as1-Casein protein was elevated in the cytoplasm of almost all BPH specimens (90.9%, Table 1 ). In contrast, 100% of the normal prostate tissues and 70% prostate cancer tissues were stained negative ( Figure 3) . As prostate cancer cells express low or undetectable levels of as1-Casein, the casein-positive hyperplastic cells can be identified, which may allow accurate clinical assessment of the disease. It is reasonable to suggest that as1-Casein may have a potential to be used as a diagnostic marker of BPH and/or the differential diagnostic marker between BPH and prostate cancer.
The caseins are a family of four acidic phosphoproteins (as1-, as2-, b-and k-Casein) that are synthesized under multihormonal control in the lactating mammary glands of mammals and comprise 40% of the proteins in human Evidence of a novel biomarker, as1-Casein K Xu et al milk.
16 as1-Casein is required for transporting the caseins from the endoplasmic reticulum to the Golgi apparatus.
17 as1-Casein and b-Casein are synthesized during the estrous stage of cycling in virgin mice and the initial stage of pregnancy. Immunohistological studies revealed that casein components are present in the cytoplasm of almost all luminal epithelial cells of lactating glands, suggesting the potential ability of epithelial cells to synthesize caseins. 18 Recently, it was reported that as1-Casein is upregulated by prolactin (PRL), one of the predominat hormones to influence prostate function and the development of mammary cells. 19 In addition, transgenic mice overexpressing the rat PRL gene develop dramatic enlargements of the prostate gland. The proliferation and secretory activities of prostate epithelial cells are stimulated by PRL in rodents and men. 20 It is suggested that PRL may play an essential role in the development of prostate hyperplasia through direct effect on the prostate gland or via increased serum levels of testosterone. 21 As the expression of as1-Casein is regulated by PRL in different animal models. 19, [22] [23] [24] It is possible that as1-Casein may act as a downstream factor of PRL which plays a key role in the development of BPH.
Currently, techniques such as urogynamic and transrectal ultrasound are used in the diagnosis of BPH. Our findings that as1-Casein is overexpressed on BPH cells may provide an additional histological marker at cell biology level to assist clinical diagnosis of this disease. For instance, immunohistological staining of biopsies with as1-Casein may be able to further confirm the presence of BPH. In addition, the fact that as1-Casein is uniquely detected in the EPS of BPH samples may facilitate the future development of a bioassay for diagnosis of BPH. Futhermore, we are in the process of investigating as1-Casein expression in the blood of BPH patients with an aim at developing a novel clinical text for diagnosis of BPH. Figure 3 Summary of as1-Casein immunoreactivity in human normal prostate, benign prostate hyperplasia (BPH) and prostate cancer tissues. Note that majority of BPH tissues (90%) showed moderate (indicated ' þ þ ') to heavy (indicated ' þ þ þ ') staining intensity.
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